title: Surgical morbidity in severely obese liver transplant recipients - a single Canadian Centre Experience.
abstract: The prevalence of obesity is increasing globally, with nearly half of a billion of the world's population now considered to be overweight or obese. Obesity and overweight patients are one of the major health issues in Canada, resulting in approximately 57,000 deaths related to obesity over the last 15 years. The effect of obesity on outcomes following liver transplantation remains largely unclear. To determine the effect of obesity on outcome we reviewed 167 liver transplants, performed at the Vancouver General Hospital, between February 1999 and October 2003. Severe obesity was defined as body mass index (BMI) > 35 kg/m2 and moderate obesity as BMI of 30 - 34 kg/m2. One hundred forty three transplants were performed in patients with a body mass index (BMI) < 30 kg/m2, 14 in patients with a BMI of 30 - 34 kg/m2, and 10 in patients with a BMI > 35 kg/m2. Non-weight related patient demographics were similar between the groups. A very high proportion of Hepatitic C patients (7/10) were observed in the severely obese group. In the early postoperative course severely obese patients had a higher rate of wound infection (20% vs. 4%, p = 0.0001) and wound dehiscence (40% vs. 1.2%, p = 0.0001). Within the first twelve postoperative months severely obese liver transplant recipients had a higher rate of ventral wound herniation (30% vs. 2.8%, p = 0.0001) when compared to obese or non-obese recipients. The one-year graft and patient survival were similar to non-obese patients. An increased BMI in liver transplant recipients in our centre did not increase the risk of early postoperative mortality, but did increase surgical complications, such as wound infection and wound dehiscence. The 1-year patient and graft survival however was indistinguishable from those of non-obese patients.
authors.affiliation: Department of Pathology, The University of British Columbia Vancouver, BC Canada. david.schaeffer@web.de
authors.forename: David F
authors.initials: DF
authors.lastname: Schaeffer
authors.forename: Eric M
authors.initials: EM
authors.lastname: Yoshida
authors.forename: Andrej K
authors.initials: AK
authors.lastname: Buczkowski
authors.forename: Stephen W
authors.initials: SW
authors.lastname: Chung
authors.forename: Urs P
authors.initials: UP
authors.lastname: Steinbrecher
authors.forename: Siegfried E
authors.initials: SE
authors.lastname: Erb
authors.forename: Charles H
authors.initials: CH
authors.lastname: Scudamore
mesh_terms: D000328:Adult; D015992:Body Mass Index; D002170:Canada / Q000453:epidemiology; D005260:Female; D006085:Graft Survival; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000401:mortality* / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000401:mortality* / Q000601:surgery; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D013529:Surgical Wound Dehiscence / Q000209:etiology; D013530:Surgical Wound Infection / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome